Member Info for JPP8788

Had this stock in the bottom drawer!

Anyone any idea what's going on here? Seafox buying?

I don't think the market will like that RNS

Hope I'm wrong.

I don't think so.

A belated Happy Birthday to Antos Glowgowski for May 30th.

What better present to give yourself and shareholders alike - a potential multi billion pound patented technology that meets an unmet clinical demand for early detection of breast cancer.

The next few weeks look rosy.

Three fantastic and highly relevant articles for you all to read in the back garden with a few beers today! All articles written in the last 48 hours.

#1 clinical research shows that localised radiation and therapy does NOT prolong life expectancy of women with stage 4 breast cancer vs traditional treatments

#2 writes about Pfizers announcement on Friday that their highly coveted Ibrance drug does NOT have an effect when added to post surgery medicine in terms of relapse and reoccurance of breast cancer. Pfizer shares down 7% late on Friday (market was expecting positive news)

#3 discusses the importance of early diagnosis for breast cancer in low to middle income countries.

https://www.news-medical.net/amp/news/20200529/Radiation-and-surgery-do-not-prolong-survival-in-newly-diagnosed-metastatic-breast-cancer.aspx

https://www.fiercepharma.com/pharma/pfizer-s-ibrance-misses-shot-at-big-new-market-early-breast-cancer-failure

https://www.statnews.com/2020/05/30/earlier-diagnosis-big-impact-global-breast-cancer/

Enjoy.

Three fantastic and highly relevant articles for you all to read in the back garden with a few beers today! All articles written in the last 48 hours.#1 clinical research shows that localised radiation and therapy does NOT prolong life expectancy of women with stage 4 breast cancer vs traditional treatments#2 writes about Pfizers announcement on Friday that their highly coveted Ibrance drug does NOT have an effect when added to post surgery medicine in terms of relapse and reoccurance of breast cancer. Pfizer shares down 7% late on Friday (market was expecting positive news) #3 discusses the importance of early diagnosis for breast cancer in low to middle income countries. https://www.news-medical.net/amp/news/20200529/Radiation-and-surgery-do-not-prolong-survival-in-newly-diagnosed-metastatic-breast-cancer.aspxhttps://www.fiercepharma.com/pharma/pfizer-s-ibrance-misses-shot-at-big-new-market-early-breast-cancer-failurehttps://www.statnews.com/2020/05/30/earlier-diagnosis-big-impact-global-breast-cancer/Enjoy.

Breast
Oncology
Using
Leading
Diagnosis

Or similar... Interesting that we've never known the origins of the name Bould? Maybe they were known all along..!

Ha. Interesting.

Here's the thing - I know I'm blue sky thinking.. But why the hell not? We've all come to terms with our BOU investment being written off... So much so that when I consider what I left in at suspension, it shocks me!

But with that said - the link that I've found works on so many levels..

Just to summarise:

Syms background in genomics, life sciences, breast cancer (metastatis).. Direct tie in with Tiziana. Syms would presumably stay on the board of the new company.. Tiziana CEO Cerrone says he wants "specialised expertise" running alongside existing management of Tiziana. Syms provides that. Win/win.

The timescales work. For all of our frustration about suspension and lack of updates.. If stemprinter was always the target, then we were never going to be able to do much until the research papers were published and the evidence was scientifically proven. Cerrone now knows he has a technology 30-50% better than Oncotype DX.

Cerrone said last week he wants a spin out of StemPrintER which is debuting at ASCO today and this weekend.. The current market leader oncotype DX sold for 2.8 billion dollars less than a year ago. Cerrones interview said he wanted a listing on "the London Market". BOU's current status allows a LSE listing much quicker than any other method. A "London listing" also allows Antos to exercise his warrants, as they had to be on a European exchange. Why did Tiziana not want a US listing? Warrants.

Previous BOU company update said we had been looking into an acquisition "for some time" in the biotechnology field. This acquisition comprises a technology for unmet clinical demand for a specific cancer (quite clearly breast cancer) whereby early detection is key to 5 year survival rates. This is unequivocally StemPrintER IMO.

There is a link to the background of tiziana and its scientists/researchers (generally Italian) and Martin Lampshire (NED of a company in Palermo).. Tenuous link I know.. But I'm taking anything I can find!

Syms set up a metsatatis lab at Oxford University some years ago. I find it extremely unlikely that he's not "in the loop" and is quite probably very excited about the potential of StemPrintER.

And finally - Syms has experience of other "spin outs" having successfully span "ANTnano" out of the University of Sunderland onto AIM around ten years ago.

Make of all that what you will.. But I'm excited.

Asco apparently has over 4000 registered members (all generally of a medical professional background)

I would suspect Syms will be present, regardless of the investment.

The 800 samples bit is new?

StemPrinter methodology (being presented at the ASCO this weekend...

"Methods:
The likelihood ?2 (LR?2) and ******-Meier survival analyses were used to assess prognostic information provided by SPRS, RS and the clinical treatment score (CTS) in 818 TransATAC patients treated with anastrozole or tamoxifen for 5 years. Comparative analyses were made for DM risk over the 10-year follow-up, as well as in the early (0-5 years) or late (5-10 years) interval, according to nodal status."

Our own most recent RNS:
" To that end the Company, together with its various professional advisers, has been working for some time to complete the acquisition of an identified target (the "Target") in the biotechnology sector (the "Proposed Transaction"). The Proposed Transaction , if completed, would comprise the acquisition of a company with a technology and patent portfolio focussed on the early detection of a specific cancer. This is an exciting opportunity to provide a new diagnostic test for cancer that addresses unmet clinical need for early detection. Early detection is proven to increase five year survival rates. "

COME ON EVERYONE!?

https://twitter.com/MadelaineH0lden/status/988735796562841601?s=20

There's a cheeky link to our CEO Allan Syms sat in front of a slide reading "The Evolution of the Life Sciences Investment Industry" at Biotrinity 2018.

As others have commented - probably something and nothing.. But there's certainly at tenable link to Syms and Tiziana!

Update from proactive investors.

https://www.proactiveinvestors.co.uk/companies/news/920520/cobra-resources--craig-moulton-updates-on-recent-positive-stage-2-sampling-results-at-wudinna-920520.html

Make your own judgement calls..
But I'm topping up here.

Doesn't the nature of a cash shell depend on the equity split?

Just because BOU are getting StemPrintER, doesn't mean that they'll get more than, say, 1% of the shares issued??

Wouldn't have thought they'll need much funding. Take some from a cash shell and be bought out very quickly.

Lots of ii's doing the same thing with many shares. Cash is king and if you're illiquid you're in trouble. They may well already be at 3/4/5x profit

From the company update RNS

"Early detection is proven to increase five year survival rates."

That, IMO, is the clearest pointer we currently have to BOU wanting to list a breast cancer genomics company.

1+1 may well equal 3 until we know different, but this is as excited I've been about BOU's future in many, many months.

Good luck

So cerrone says they want specialised expertise within the new company to run alongside existing management... I wonder is Syms would be interested in that! Duh!

Absolute dead cert based on the research I've done (and I havent posted even half of it...)

Pretty sure he said 100% to existing holders?

You won't be diluted when if it does spin off.

I'm sorry but £150m mcap?

Seeya!! This is going places.